HPGC Renmintongtai Pharmaceutical Corporation

SHSE:600829 Stock Report

Market Cap: CN¥4.7b

HPGC Renmintongtai Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

HPGC Renmintongtai Pharmaceutical has been growing earnings at an average annual rate of 6.9%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 6% per year. HPGC Renmintongtai Pharmaceutical's return on equity is 9%, and it has net margins of 2.5%.

Key information

6.9%

Earnings growth rate

7.0%

EPS growth rate

Healthcare Industry Growth7.0%
Revenue growth rate6.0%
Return on equity9.0%
Net Margin2.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

HPGC Renmintongtai Pharmaceutical Corporation's (SHSE:600829) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 15
HPGC Renmintongtai Pharmaceutical Corporation's (SHSE:600829) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Is HPGC Renmintongtai Pharmaceutical (SHSE:600829) A Risky Investment?

Oct 01
Is HPGC Renmintongtai Pharmaceutical (SHSE:600829) A Risky Investment?

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Might Be Having Difficulty Using Its Capital Effectively

Sep 05
HPGC Renmintongtai Pharmaceutical (SHSE:600829) Might Be Having Difficulty Using Its Capital Effectively

Revenue & Expenses Breakdown

How HPGC Renmintongtai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:600829 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2410,2432585310
30 Jun 2410,1002745390
31 Mar 2410,3352995360
31 Dec 2310,3902925440
30 Sep 2310,2103135340
30 Jun 2310,3123125260
31 Mar 239,9662905100
31 Dec 229,6412644950
30 Sep 229,3362355190
30 Jun 229,2562475340
31 Mar 229,4822835390
31 Dec 219,3152775540
30 Sep 219,5402396270
30 Jun 219,1672016370
31 Mar 218,2931376260
31 Dec 208,0051456330
30 Sep 207,8771995500
30 Jun 207,9192075480
31 Mar 208,2632425950
31 Dec 198,3542675970
30 Sep 197,8872655680
30 Jun 197,5352645570
31 Mar 197,3142625170
31 Dec 187,0552584990
30 Sep 187,1172485200
30 Jun 187,4632495260
31 Mar 187,6372585280
31 Dec 178,0092545350
30 Sep 178,6412395970
30 Jun 178,4922385500
31 Mar 178,7802275770
31 Dec 169,0062255620
30 Sep 168,7251965370
30 Jun 168,6061605020
31 Mar 168,5081405220
31 Dec 158,9091397020
30 Sep 158,9941627650
30 Jun 159,1561639610
31 Mar 159,2092001,1090
31 Dec 149,0111871,1930
30 Sep 147,6822361,2720
30 Jun 146,2901631,3250
31 Mar 144,896501,3030
31 Dec 133,17761,2190

Quality Earnings: 600829 has high quality earnings.

Growing Profit Margin: 600829's current net profit margins (2.5%) are lower than last year (3.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600829's earnings have grown by 6.9% per year over the past 5 years.

Accelerating Growth: 600829's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600829 had negative earnings growth (-17.7%) over the past year, making it difficult to compare to the Healthcare industry average (-5.7%).


Return on Equity

High ROE: 600829's Return on Equity (9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HPGC Renmintongtai Pharmaceutical Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xian Chao ZhangChina Stock Investment Research Co. Ltd. (GZ500..com)
Hai Zhu PengHuatai Research
Yin YePing An Securities Co. Ltd.